Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NextCure, Inc. (NXTC : NSDQ)

• Company Description    NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. Number of Employees: 87

• Price / Volume Information    Yesterday's Closing Price: $3.64 Daily Weekly Monthly 20 Day Moving Average: 148,545 shares Shares Outstanding: 27.75 (millions) Market Capitalization: $101.00 (millions) Beta: 0.15 52 Week High: $9.18 52 Week Low: $3.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.04% -13.32% 12 Week -27.20% -19.96% Year To Date -39.33% -25.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9000 VIRGINIA MANOR ROAD SUITE 200 - BELTSVILLE,MD 20705 USA ph: 240-399-4900 fax: - ir@nextcure.com http://www.nextcure.com

• General Corporate Information    Officers Michael Richman - President; Chief Executive Officer and Director David Kabakoff - Chairman of the Board Steven P. Cobourn - Chief Financial Officer Anne Borgman - Director Ellen G. Feigal - Director Peer Information NextCure, Inc. (CORR.) NextCure, Inc. (RSPI) NextCure, Inc. (CGXP) NextCure, Inc. (BGEN) NextCure, Inc. (GTBP) NextCure, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 65343E108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 27.75 Most Recent Split Date: (:1) Beta: 0.15 Market Capitalization: $101.00 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.68 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.47 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -23.33% vs. Previous Quarter: -21.31% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -30.64 12/31/21 - -27.09 09/30/21 - -25.04 ROA 03/31/22 - -29.43 12/31/21 - -26.02 09/30/21 - -24.02 Current Ratio 03/31/22 - 32.52 12/31/21 - 34.48 09/30/21 - 32.95 Quick Ratio 03/31/22 - - 12/31/21 - 34.48 09/30/21 - 32.95 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 7.71 12/31/21 - 8.45 09/30/21 - 8.99 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©